REGENERX BIOPHARMACEUTICALS, INC. (OTCMKTS:RGRX) Files An 8-K Regulation FD Disclosure

Item 7.01.

On March 13, 2017, the Company issued a press release announcing
the posting of a letter to shareholders issued by Company. A copy
of the letter is furnished as Exhibit 99.1 to this Current
Report.

Forward-Looking Statements

The Presentation Materials contains certain forward-looking
statements that involve risks and uncertainties that could cause
actual results to be materially different from historical results
or from any future results expressed or implied by such
forward-looking statements. Examples of such forward-looking
statements include statements concerning the target dates for
completing the companys or its partners ongoing clinical trials
for ophthalmic and orphan indications, the potential size of
addressable markets, including the market for eye drops and
parenteral delivery products, the companys ability to enter into
any collaborations with respect to the development or
commercialization of its product candidates, and the therapeutic
potential of T4 for ophthalmic, cardiovascular and neurovascular
disorders. Factors that may cause actual results to differ
materially from any future results expressed or implied by any
forward-looking statements include the risk that although T4 has
demonstrated potential therapeutic benefit for dermal,
ophthalmic, cardiovascular and neurovascular disorders, the
companys product candidates may not demonstrate safety and/or
efficacy in clinical trials, the risk that encouraging results
from early research, preclinical studies, compassionate use or
clinical trials may not be confirmed upon further analysis of the
detailed results, the risk that additional information relating
to the safety, efficacy or tolerability of our product candidates
may be required by regulatory agencies, the risk that the company
or its licensees will not obtain approval to market the companys
product candidates in the U.S. or abroad, the risks associated
with reliance on outside financing to meet capital requirements,
the risks associated with reliance on licensees for the funding
or conduct of further development and commercialization
activities relating to the companys product candidates, the risks
that the companys patents will not be enforceable or expire prior
to commercial marketing, and such other risks described in the
companys latest Annual Report on Form 10-K, and other filings the
company makes with the SEC. Any forward-looking statements are
made to Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as
amended, and, as such, speak only as of the date made. The
Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new
information, future events or otherwise.

(d)Exhibits

About REGENERX BIOPHARMACEUTICALS, INC. (OTCMKTS:RGRX)

RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The Company has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.

REGENERX BIOPHARMACEUTICALS, INC. (OTCMKTS:RGRX) Recent Trading Information

REGENERX BIOPHARMACEUTICALS, INC. (OTCMKTS:RGRX) closed its last trading session 00.000 at 0.289 with 13,800 shares trading hands.